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Introduction 
Thymidine phosphorylase (TP) is a nucleoside metabolism enzyme that plays an important 
role in the pyrimidine salvage pathway. It was first described in 1953 when it was found that 
TP catalyses the reversible conversion of thymidine (TdR) and 2’-deoxyuridine to thymine 
and 2-deoxy-D-ribose-1-phosphate [1]. Although this reaction is reversible the main function 
of TP is catabolic [2].  2-deoxy-D-ribose-1-phosphate is dephosphorylated to the endothelial 
chemoattractant 2-deoxy-D-ribose (D-dRib) (figure 1) [2-5]. D-dRib is a downstream 
mediator of TP function, promoting angiogenesis and chemotactic activity of endothelial cells 
and conferring resistance to hypoxia induced apoptosis in cancer cells.  
In addition to its metabolic function, TP plays a key role in angiogenesis [3,4]. TP and the 
angiogenic factor platelet-derived endothelial-cell growth factor (PD-ECGF) are, in fact, 
different names for the same molecule [3,5,6]. Gliostatin is a polypeptide that has inhibitory 
effects on astrocytes and glial cells and promotes endothelial cell growth. Gliostatin amino 
acid sequence is completely identical to TP/PD-ECGF [7]. TP is overexpressed by several 
human cancers and is associated with poor outcome. 
In their landmark paper Hanahan and Weinberg described eight hallmarks that explain the 
behaviour of cancer cells; self-sufficiency in growth signals, resistance to antigrowth signals, 
evasion of apoptosis, limitless replicative capability, reprograming of cellular metabolism, 
evasion of elimination by immune system, invasion and angiogenic capabilities [8]. Research 
over the past fifty years has shown that TP plays a significant role in these hallmarks. We 
present here a review of the accumulating evidence of the function of TP in human cancer. 
We further discus the complexity of TP dual role in cancer: aiding cancer progression on one 
hand and determining response to some therapeutic agents on the other. 
 
 
TP in normal tissue 
The human TP gene is located on chromosome 22q13 [9]. TP is a homodimer, consisting of 
two identical subunits that are non-covalently associated with a dimeric molecular mass 
[4,10]. Each subunit is composed of a small α-helical domain that contains the thymidine-
binding site and a large α/β domain that contains the phosphate binding site [10]. High levels 
of TP are expressed in macrophages, stromal cells, glial cells, some epithelia [11]. It is 
expressed in the nucleus where it modulates the pool of pyrimidine for DNA synthesis and 
also in cytoplasm where it plays different enzymatic functions [11].  
Most TP activity present in normal human blood resides in the cytoplasm of platelets [12]. 
This suggests that blood platelets play an important role in thymidine metabolism. It has been 
suggested that this role is part of the physiological functions of platelets [13]. Activated 
platelets release TP to stimulate angiogenesis by enhancing endothelial cell motility and 
proliferation [13].  The physiological role of TP in angiogenesis extends to the female 
menstrual cycle. In normal proliferative endometrium, TP is found exclusively in the basal 
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layer and the inner third of the functionalis; expression is cytoplasmic in glandular epithelium 
and nuclear in stromal cells. At the end of the menstrual cycle TP becomes expressed 
uniformly in the epithelium of all endometrial glands, with nuclear and cytoplasmic 
expression. At this stage there is very little stromal expression of TP [14,15].  A more 
detailed description of the role of TP in angiogenesis is provided below. 
Transcriptional control of TP and its upregulation in cancer 
TP is overexpressed in oral squamous carcinoma [16], oesophageal [4], gastric [17], breast 
[18], lung [19-21], colorectal [22], bladder [23], and cervical cancer [24]. TP is expressed by 
tumour cells and in the tumour microenvironment by fibroblasts, tumour associated 
macrophages (TAMs) and lymphocytes [3,4,17-23,25]. Several studies have shown that TP is 
elevated in cancer patients’ plasma [25]. 
Factors that lead to TP overexpression in tumour cells include inflammatory cytokines, 
cellular stress like hypoxia and low PH, chemotherapy and radiotherapy (figure 2). Of the 
inflammatory cytokines tumour necrosis factor α (TNFα) plays an important role in the 
regulation of TP expression. The TP gene has a transcriptional factor SP1 binding site within 
its promoter region. TNFα activates SP1 which in turn binds to the promoter region of TP 
gene leading to expression of the TP protein. Activation of NFκB is another mechanism by 
which TNFα leads to TP overexpression in cancer [25-27]. Interferon (IFN) α, β and γ 
activate the IFN-stimulated response element (ISRE) and signal transduction and activator of 
transcription 1 (STAT1) causing expression of TP [25,28].  Other inflammatory factors that 
have been reported to upregulate TP include hypoxia inducible factor 2α (HIF-2α), 
interleukin 1 (IL-1) and interleukin 10 (IL-10) [3, 25]. IFNα/γ stabilizes TP mRNA levels 
leading to a rise in TP enzyme activity. Epigenetic modulation regulates TP expression at the 
transcriptional level in breast cancer and colon cancer [25]. 
Chemotherapy agents like docetaxel, paclitaxel, cyclophosphamide, and oxaliplatin can 
increase TP levels possibly through the induction of inflammatory cytokines like INF and 
TNF [25,29].  
There is little evidence for TP gene mutation in tumour cells, the fact that TP levels are 
elevated in non-malignant cells in the tumour microenvironment (TME) suggest that raised 
TP expression is influenced by local inflammation and stress conditions like hypoxia in the 
TME rather than genetic changes. This is supported by the observation of increased TP levels 
in non-malignant chronic inflammatory conditions like arthritis and psoriasis [27]. 
The role of TP in angiogenesis  
Angiogenesis is the formation of new blood vessels from pre-existing vasculature. It is 
essential for tumour growth and cancer progression. TP’s function as an angiogenic factor is 
well established. It enhances angiogenesis within the tumour by two mechanisms; (i) by 
stimulating endothelial cell migration and (ii) by stimulating the release of angiogenic factors 
from malignant cells and stromal cells in the tumour microenvironment (figure 1).  
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The angiogenic function of TP is related to its enzymatic activity. It has been shown that 
blocking the enzymatic function of TP abolishes its angiogenic function [30,31]. The effects 
of TP on angiogenesis are mediated through the thymidine metabolite deoxy-D-ribose which 
results from dephosphorylation of deoxy-D-ribose-1-phosphate and then released out of the 
cell [30-33]. Deoxy-D-ribose stimulates endothelial cells migration by several mechanisms. 
Firstly, it stimulates the phosphorylation of tyrosine 397 of the focal adhesion kinase (FAK). 
FAK is non-receptor tyrosine kinase that has a role in cell migration and cell death [32,34]. 
Secondly, deoxy-D-ribose activates cell surface integrins leading to focal adhesion formation 
[34]. Thirdly, it activates p70/s6k, an important downstream kinase of the mTOR pathway 
regulating cell proliferation and angiogenesis [34]. A study of migration of human umbilical 
vein endothelial cells (HUVECs) found that deoxy-D-ribose-mediated angiogenesis is 
inhibited by rapamycin through blocking p70/s6k kinase activation [4]. Lastly deoxy-D-
ribose provides an energy source for migrating endothelial cells and induces pseudopodia 
formation [32].  
TP stimulates angiogenesis indirectly by enhancing the release of angiogenic factors [34,35]. 
Bijnsdorp and colleagues studied TP effects by exposing human umbilical vein endothelial 
cells (HUVECs) to conditioned medium derived from human colon cancer cell lines with 
high and no TP expression [34]. They found that TP-expressing cells secreted angiogenic 
factors (IL-8, bFGF and TNFα) that stimulated endothelial cells migration and invasion, but 
not proliferation. Inhibition of only one of these factors using blocking antibodies resulted in 
a complete inhibition of the angiogenic effects, suggesting that a combination of these 
angiogenic factors might be responsible for the angiogenic effects of TP. An interesting 
finding from this study was that TP did not increase the invasiveness or migration capacity of 
the cancer cells. An important finding reported was that VEGF secretion was not increased 
with high TP expression. This finding is consistent with results of an earlier retrospective 
study of TP and VEGF expression in 223 tumour specimens from lung cancer patients [36]. 
In the latter study evaluation of TP and VEGF expression in cancer cells revealed a weak 
positive correlation between the two angiogenic factors. Similar observation has been 
reported in colorectal cancer [36]. However, other reports show increased VEGF amounts in 
high TP-expressing tumours [34].  VEGF is known to be expressed in response to hypoxia 
inducible factor-1α (HIF-1α). HIF-1α is upregulated in response to hypoxia; it forms a dimer 
with HIF-1β increasing the expression of VEGF. On the other hand, TP expression has been 
linked to HIF-2α in several human cancers. Xian-hua et al. recently published a study on the 
correlation of HIF-1α and HIF-2α with angiogenic factors in non-small cell lung cancer 
(NSCLC) [37]. Tumour samples from 140 patients with NSCLC were retrospectively 
assessed for expression of HIF-1α, HIF-2α, TP, VEGF and cyclooxygenase (COX)-2. A 
significant correlation was detected between HIF-1α and VEGR expression while no 
correlation was shown between HIF-2α and VEGF expression. The correlation between HIF-
2α and TP was statistically significant while no correlation was found between TP and HIF-
1α expression. Authors have hypothesized that increasing oxygen supply from the newly 
formed blood vessels reduces the degree of hypoxia in the tumour microenvironment leading 
to rapid downregulation of HIF-1α and upregulation of HIF-2α which in turn promotes 
activation of TP and COX-2 to maintain angiogenesis. In this model, VEGF plays a dominant 
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role in the initiation of the angiogenic switch whereas TP contributes to the maintenance of 
angiogenesis. It is important to note that some tumours have high microvascular density and 
do not express TP or VEGF [36]. Clearly other mechanisms of angiogenesis are involved in 
these tumours. 
TP and evasion of apoptosis  
TP inhibits hypoxia-induced apoptosis, as well as protecting cancer cells from apoptosis 
induced by chemotherapy agents such as cisplatin and antimircotubular drugs. Mechanisms 
involved in the antiapoptotic role of TP include; (1) inhibition of mitochondrial release of 
cytochrome C [38], (2) upregulation of Bcl-2 and Bcl-xL [38], (3) suppression of the 
phosphorylation of p38 MAPK and (4) inactivation of caspase 3 and 9 [39]. 
Mitogen-activated protein kinase (MAPK) cascades are key signalling pathways involved in 
the regulation of normal cell proliferation, survival and differentiation. Aberrant regulation of 
MAPK pathway contributes to cancer and other disease. The, p38 MAPK pathway, plays a 
dual role depending on the stimulus, mediating either cell survival or death through different 
mechanism including apoptosis. It mediates apoptosis by phosphorylation of the proapoptotic 
protein BAX with subsequent release of mitochondrial cytochrome C and activation of 
caspases [40]. Ikeda et al. examined the role of TP metabolite, deoxy-D-ribose, in preventing 
hypoxia induced-apoptosis in human leukaemia cell lines HL-60 and Jurkat cells [41]. Under 
normoxic conditions, no apoptotic cells were observed in un-treated Jurkat cells and 
treatment with deoxy-D-ribose had no effect on cell morphology. However, under hypoxic 
conditions chromatin condensation was observed in Jurkat cells. When cells were treated 
with deoxy-D-ribose, this hypoxia-induced morphological change was not observed. 
Furthermore, authors found that under hypoxic conditions the activation of p38 MAPK 
promoted translocation of Bax from the cytosol to the mitochondria and HL-60 cell death. 
Deoxy-D-ribose reduced the level of Bax attached to mitochondria in hypoxic conditions 
resulting in inhibition of apoptosis.  Authors concluded that deoxy-D-ribose inhibits hypoxia-
induced apoptosis by suppressing the phosphorylation of p38 MAPK. This study did not 
show the mechanisms by which deoxy-D-ribose prevent the phosphorylation of p38 MAPK. 
Another study by the same group, Ikeda and colleagues, examined the effect of TP on key 
regulators of hypoxia-induced apoptosis, HIF-1α, caspase 3 and BNIP3 [39]. Using human 
leukaemia and human colon cancer cell lines, researchers showed that under hypoxic 
conditions HIF-1α, caspase 3 and BNIP3 were suppressed in TP-overexpressing cells 
compared to control cells. 
An interesting report investigated the effects of TP overexpression on cisplatin-induced 
apoptosis used human leukaemia Jurkat cell transfected with wild type or mutant TP cDNA 
[42]. Wild type and mutant TP inhibited a number of steps in the cisplatin-induced apoptotic 
pathway, activation of caspases 3 and 9 and mitochondrial cytochrome c release. It is 
important to note that mutant TP lacks its enzymatic activity indicating that the ability of TP 
to inhibit apoptosis induced by cisplatin is independent of its enzymatic activity. 
The Role of TP in invasion and metastasis 
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TP plays a role in tumour invasiveness by enhancing the expression of genes involved in the 
epithelial to mesenchymal transition program. Factors reported to be expressed in response to 
TP include; matrix metalloproteinases (MMP-1, MMP-7, MMP-9), Urokinase-type 
plasminogen activator (uPA) and VEGF [45]. A possible mechanism by which TP enhances 
the expression of these genes is via activation of the PI3K-Akt pathway. Akt is a mediator of 
Activator Protein-1 (AP-1) induction. The AP-1 site is upstream of the transcriptional start 
sites of MMP-7, MMP-9 and MMP-1 and has long been thought to play a dominant role in 
the transcriptional activation of the MMP promoters [45]. Inhibition of TP leads to decreased 
levels of MMP-9 mRNA levels with resultant reduced malignant cells invasiveness [46]. 
Research has shown that KB cells (human epidermal carcinoma) transfected with TP cDNA 
had more invasive potential and metastatic phenotype than KB cells transfected with mock 
vector [43]. In a study by Sato et al, it was found that TP promoted invasive activity and 
metastatic phenotype in lung adenocarcinoma. This group has reported that inhibition of TP 
strongly suppressed lung metastasis in nude mice [44]. 
TP and cancer cell evasion of immune cells 
The cell-surface Fas receptor (FasR), also termed apoptosis antigen-1 (Apo-1) or cluster of 
differentiation 95 (CD95), is a member of the tumour necrosis factor (TNF) family of 
receptors [47]. FasR is a death receptor that leads to programmed cell death (apoptosis). 
Binding of Fas to its ligand Fas-L leads to activation of the Fas-induced apoptosis pathway. 
This pathway is one of the pathways by which cytotoxic T-lymphocytes (CTLs) induce cell 
death as CTLs express Fas-L upon their activation [47]. Several reports have shown that TP 
overexpression leads to inhibition of Fas induced apoptosis [48,49]. A study where KB/TP 
cell lines (a human epidermoid carcinoma KB cell line transfected with TP cDNA and 
expressing TP) were used to examine the role of TP on Fas-induced cell death showed that 
TP expression interfered with the release of cytochrome c and caspase-3 cleavage 
independent of its enzymatic activity. This is in contrast to the angiogenic and chemotactic 
effects of TP where its enzymatic activity is essential to exert its effects as discussed earlier 
[48].  
It has been reported that TP can suppress the innate immune response to tumour cells via 
increasing the secretion of IL-10, which inhibits the anti-inflammatory functions of dendritic 
cells (DC) and macrophages [25]. IL-10 can modulate the expression of other cytokines, 
soluble mediators and cell surface molecules by cells of myeloid origin, particularly 
macrophages and DC. IL-10 is also able to inhibit COX-2 expression, IL-6, IL-12, and TNF-
α [25]. This is a possible indirect mechanism of immunomodulation by TP favouring tumour 
growth and progression. 
Slager and colleagues examined the use of TP as a potential target for immunotherapy of 
cancer [49]. Authors isolated tumour reactive CD8+CTLs clones from peripheral blood of a 
patient successfully treated with donor lymphocyte infusion (DLI) for relapsed multiple 
myeloma after HLA-matched allogeneic stem cell transplantation (SCT). These CTLs were 
directed against TP. The epitope recognized by the CTLs was encoded by a single nucleotide 
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polymorphism (SNP), resulting in a TP-1 mHag. This SNP has been reported previously as a 
mutation associated with the autosomal recessive disease mitochondrial neurogastrointestinal 
enchephalomyopathy (MNGIE). The fact that T-cells directed against TP were isolated from 
a patient with multiple myeloma showing complete remission after cellular immunotherapy 
led authors to conclude that generation of T-cell responses to polymorphisms in TP gene may 
be a potent combination of direct antitumour immunotherapy and antiangiogenic treatment. 
The researchers go further to predict that TP can be a potential target not only in 
haematological malignancies but in solid tumours as well. 
Effects on other hallmarks of cancer  
TP aids the uncontrolled growth of malignant cells indirectly by enhancing angiogenesis 
which provides cancer cells with necessary oxygen, nutrients and mitogens required for 
growth. Furthermore, TP is a key enzyme in nucleoside metabolism salvage pathway; it 
maintains the pool of thymine in the body which is required for DNA synthesis. 
Stabilizing telomere length to enable limitless replication of cancer cells and reprogramming 
the cellular metabolism machinery are other important hallmarks of cancer. Currently there is 
no evidence for TP contribution to these two hallmarks. However as discussed earlier in this 
review, hypoxia is an important factor that induces TP expression, other factors upregulated 
in hypoxia include HIF-1α which plays a significant role in shifting the cellular metabolism 
from mitochondrial oxidative phosphorylation to glycolysis.  
TP as a predictive and prognostic biomarker  
5-fluoropyrimidine (5-FU) is an antimetabolite drug that works by inhibiting the synthesis of 
DNA and RNA [50]. The mechanism of 5-FU cytotoxicity has been ascribed to the 
misincorporation of fluoronucleotides into RNA and DNA and the inhibition of the 
nucleotide synthetic enzyme thymidylate synthase (TS) [50]. 5-FU is converted 
intracellularly to several active metabolites; fluorodeoxyuridine monophosphate (FdUMP), 
fluorodeaoxyurinidine triphosphate (FdUTP) and fluorouridine triphosphate (FUTP) [50]. 
These metabolites disturb the action of TS required for RNA synthesis. Since the 1950s 5-FU 
has been the backbone of chemotherapy in colorectal cancer; it is widely used in cancers like 
breast carcinoma and head and neck cancers. TP converts 5-FU to fluorodeoxyuridine 
(FUDR), which is then phosphorylated by thymidine kinase (TK) to FdUMP [50]. TP 
overexpression in cell culture and xenograft models had been shown to increase sensitivity to 
5-FU due to enhanced formation of FdUMP [reviewed in 3,50]. However, in a study where 
the gene expression levels of TP were measured by quantitative reverse transcription-PCR in 
38 pretreatment biopsies of colorectal tumours from patients who were subsequently treated 
with 5-FU and leucovorin (LV), it was found that the range of TP gene expression (relative 
mRNA levels) in those tumours nonresponsive to 5-FU was much broader than that of the 
responding tumours [51]. Tumours with the highest basal TP expression were nonresponders 
to 5-FU/LV therapy. The mean TP mRNA level in the nonresponding tumours was 2.6-fold 
higher than that of the responding patients. TP and TS expressions were found to be 
independent variables in these tumours, so that low expression levels of both TS and TP in 
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tumours predicted a high response rate to 5-FU/LV as well as a significantly longer survival, 
whereas none of the patients with high expression of either TP or TS were responders [51]. In 
another study, Gustavsson et al. retrospectively examined the pretreatment expression of TP 
and other 17 genes in archival tumour samples from patients with advanced CRC to 
determine if one or more of the selected genes can be used as either a prognostic or predictive 
marker of 5-FU-based treatment outcomes [52]. One hundred and forty-four CRC patient 
samples were analysed via real-time PCR for gene expression. Univariate analyses were used 
to correlate gene expression with efficacy and time-to-event variables. Low TP gene 
expression was associated with better time-to-progression in the entire population. Low TP 
expression was independently associated with improved overall survival. Low TP gene 
expression was also predictive of response to 5-FU based chemotherapy.  
Capecitabine is an oral pro-drug of 5-FU commonly used in colorectal, gastric and breast 
cancer. Capecitabine undergoes conversion by several enzymes in the liver and finally by TP 
in the tumour to be converted into 5-FU [4].  Because the final step of metabolic conversion 
occurs within tumour cells, capecitabine potentially reduces systemic exposure to 5-FU while 
maximizing the dose-intensity of 5-FU within tumour tissue [53]. The preferential activation 
of capecitabine in tumour tissue and its dependence on TP was shown in a study of 19 
patients with colorectal cancer requiring surgical resection for primary tumour and/or liver 
metastases that were treated with capecitabine for 5-7 days prior to surgery [54]. On the day 
of surgery, samples of tumour tissue, adjacent healthy tissue and blood samples were 
collected from each patient. Concentrations of 5-FU in various tissues and plasma were 
measured. The activity of TP was measured in tissue homogenates, by catabolic assays. The 
ratio of 5-FU concentrations in tumour to adjacent healthy tissue was used as the primary 
marker for the preferential activation of capecitabine in tumour. In primary colorectal 
tumours, the concentration of 5-FU was on average 3.2 times higher than in adjacent healthy 
tissue. The mean liver metastasis/healthy tissue 5-FU concentration ratio was 1.4. Authors 
concluded that this is explained by the activity of TP in colorectal tumour tissue, which is 
approximately four times that in adjacent healthy tissue. In the liver, TP activity is 
approximately equal in metastatic and healthy tissue, which explains the lack of preferential 
activation of capecitabine in these tissues [54]. Those results are consistent with older reports 
[55]. A further study from gastric cancer examined TP as a predictive marker for capecitabine 
response. In a report by Lu and colleagues, using real time quantitative PCR they analysed 
mRNA expression levels of TP and TS in primary tumours from 57 patients with advanced 
gastric cancer [56]. It was found that low TP expression and high TS expression in gastric 
cancer specimens were linked to poor outcome in patients receiving capecitabine-based 
regimen. In contrast, the subgroup of patients with low TS and high TP expression had the 
best treatment response. Patients with high TS and low TP expression had poorest response 
rate (15.8% vs. 57.9%) and overall survival (6.6 vs. 13.8 months) compared to the patients 
with low TS/high TP expression. Authors also studied the correlation between expression of 
TS and TP and the efficacy of capecitabine combined with different cytotoxic agents 
(paclitaxel or cisplatin). They found that the expression of TS and TP was associated with a 
better tumour response. Authors concluded that the combination of TS and TP might add 
more predictive power than each gene expression alone. Another group of researchers 
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examined TP, DPD and TP/DPD ratio as predictive markers for concomitant capecitabine 
and radiotherapy in locally advanced rectal cancer in a neoadjuvant setting [57]. Tissue 
samples, both neoplastic and normal ones, were endoscopically taken from a cohort of 28 
patients before treatment for TP and DPD measurement with ELISA. Levels of TP and DPD 
in tumour tissue did not reveal any statistically significant difference between the patients 
with proven pathological group and those with no response. However, median ratio TP/DPD 
of patients with response was higher than the no response group. Authors concluded that 
TP/DPD ratio is a possible predictive factor for tumour response after concomitant 
preoperative chemoradiation with capecitabine in locally advanced rectal cancer. A 
multicentre phase II trial evaluated the predictive relevance of several biomarkers, including 
TP, on the survival of patients with stage III colorectal cancer treated with adjuvant 
chemotherapy of oral fluoropyrimidine [58]. Patients received oral doxifluridine or oral 
uracil/tegafur for 12 months with a 5-year follow-up. Outcome measures were disease-free 
survival and tissue markers; TP and DPD protein levels and TP, DPD, TS and orotate 
phosphoribosyltransferase (OPRT) mRNA levels in tumour samples and TS tandem-repeat 
type in blood samples. The study showed a significant association between the intratumoural 
TP/DPD enzyme ratio and disease-free survival. The 5-year disease-free survival rate was 
statistically significantly higher in patients with high TP/DPD ratios following adjuvant 
therapy with oral fluoropyrimidines. No significant association was observed between the 
intratumoural TP/DPD enzyme ratio and the disease-free survival rate in the doxifluridine 
group. Studies carried out in breast cancer patients strengthen the validity of TP use as a 
biomarker for oral fluoropyrmidines response [59,60]. An increase in both relapse-free 
survival and overall survival was found in TP-positive compared to TP-negative breast 
tumours in a study of 109 patients treated with adjuvant cyclophosphamide, methotrexate and 
5-FU (CMF) [61]. It important to note that no survival difference was found between TP 
positive and TP negative patients who had not received chemotherapy. There are other papers 
that have shown TP/DPD ratio is a predictive biomarker for capecitabine in head and neck 
cancer [62] and pancreatic adenocarcinoma [63]. In contrast to these findings, a phase II trial 
found no association between TP/DPD ratio and the efficacy of concomitant chemoradiation 
with capecitabine in patients with pancreatic adenocarcinoma [64]. 
Based on evidence available, it appears that TP is a valid predictive biomarker for oral 
fluoropyrimidine like capecitabine, evidence is less clear for 5-FU.  However, when it comes 
to making clinical decisions in the clinic, the available evidence is not sufficient to treat 
patients based on their TP expression status when being considered for fluoropyrimidine 
chemotherapy. Firstly, there is lack of prospective randomised data to support such practice. 
Secondly, present data on the predictive role of TP is not entirely consistent particularly in 
the case of 5-FU. As discussed earlier in this review TP plays role in cancer progression and 
angiogenesis, yet it is important in activating capecitabine to its active form 5-FU. These two 
contradicting roles, best described by one publication as a Jekyll and Hyde story [65], are 
independently related to TP expression. 
Targeting thymidine phosphorylase 
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The role of TP in cancer progression and angiogenesis, makes it an attractive target for 
therapy. Of particular interest is the inhibition of its angiogeneic effects. The formation of 
new blood vessels is essential for tumour growth, and despite the clinical success of 
antiangiogenic agents like bevacizumumab, many cancers develop resistance to the currently 
available antiangiogenic therapies [66].  Resistance to those agents that target VEGF is 
thought to be due to activation of VEGF-independent angiogenesis [67]. Therefore 
combining VEGF blockade with agents that target those VEGF-independent angiogenic like 
TP is an appealing approach [67]. Another reasonable strategy is the combination of TP-
inducing chemotherapy, such as paclitaxel, as discussed earlier in this review, with drugs 
activated by TP like capecitabine [3]. This strategy has proven to be successful in several 
human tumours [3].     
It is important to note that there are no specific TP inhibitors approved for clinical use at 
present. [3,4,28,68,69]. In 2000, Fukushima and his colleagues identified a pyrimidine 
analogue, 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1H,3H)-pyrimidine dio ne 
hydrochloride (TPI) as the most known  potent TP inhibitor [68]. They have shown that TPI 
inhibits several biological functions of TP in mouse models, since then it has been used in 
many preclinical experiments and proposed to be an effective antitumor agent. TPI and the 
antimetabolite α,α,α-triﬂ uorothymidine (FTD) have been formulated into one novel oral 
compound: TAS-102. FTD cytotoxic activity is mediated through inhibition of thymidylate 
synthase, TPI is added to TAS-102 to prevent FTD degradation by TP.  Recently published 
results of a randomised phase 2 study of TAS-102 for ﬂuorouracil-refractory colorectal 
cancer patients, showed an impressive median overall survival of 9·0 months (95% CI 7·3–
11·3) noted with TAS-102, compared with 6·6 months (4·9–8·0) for placebo [70]. These 
impressive results are not solely due to FTD effects but TPI is likely exerting antitumor and 
antiangiogenic effects [71]. Other TP inhibitors include purine analogues that have been 
shown to inhibit the enzymatic activity of TP and TP mediated angiogenesis [69]. Another 
inhibitor of the enzymatic activity of TP is 2-deoxy-L-ribose which is a stereoisomer of 
deoxy-D-ribose [69].  
A popular therapeutic approach is to combine TP-inducing agents with capecitabine, which is 
activated by TP, leading to enhanced cytotoxicity of capecitabine [72]. This approach has 
been recently studied in NSCLC [73]. Emodin, an anthraquinone derivative from the root and 
rhizome of Rheum palmatum with reported antitumor effects, was used in combination with 
capecitabine to treat human NSCLC cell line [73]. It was found that emodin increased the 
cytotoxic effects of capecitabine through enhancing TP mRNA and protein expression. It is 
important to note that capecitabine is not used clinically to treat NSCLC hence the novelty of 
this approach. Another important point is that combining capecitabine with TP-inducing 
agents like cisplatin or paclixaxel has worked successfully in clinical practise.   
A second treatment strategy is based on the finding that TP overexpression has been linked to 
cisplatin resistance [42]. Therefore, targeting the antiapoptotic effects of TP could enhance 
cisplatin cytotoxicity.  A recent publication examined the effect of TP inhibition, using Heat 
shock protein 90 (HSP90) inhibitor, on cisplatin cytotoxicity in NSCLC cell lines [74]. 
HSP90 is a molecular chaperone that is required for conformational folding and maintaining 
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the stability of numerous proteins. HSP90 was inhibited using 17-allylamino-17-
demethoxygeldanamycin (17-AAG). That resulted in decreased TP mRNA levels and cellular 
TP protein which was accompanied by a downregulation of phosphorylated MKK1/2-
ERK1/2 and AKT protein levels. Authors found that the 17-AAG treatment disrupted the 
interaction between HSP90 and TP and triggered TP protein degradation through the 
ubiquitin-26S proteasome pathway. The net result was inhibition of TP-mediated 
antiapoptosis leading to enhanced cisplatin cytotoxicity. Similar results were reported by 
another group using human hepatoma HepG2 cells [75]. Liu et al found that treating human 
hepatoma HepG2 cells with cisplatin alone led to increased TP expression through 
phosphorylation of ERK, p38 and PI3K/AKT pathways. When cells were pretreated with 
fucoxanthin, the major non-provitamin A carotenoid found in Undaria Pinnatifida, followed 
by cisplatin, a significant attenuation of cisplatin-induced TP mRNA expression was 
observed with resulting enhanced cisplatin cytotoxicity. 
Another interesting TP targeting molecule is the purine riboside derivative KIN59 (5'-O-
tritylinosine) which was identified in 2004 [76]. KIN59 was found to inhibit human and 
bacterial recombinant TP and TP-induced angiogenesis. In contrast to other TP inhibitors, 
KIN59 does not compete with the pyrimidine nucleoside or the phosphate-binding site of the 
enzyme but noncompetitively inhibits TP when thymidine or phosphate is used as the 
variable substrate [76,77]. It was shown that KIN59 completely inhibited angiogenesis in a 
chick chorioallantoic membrane (CAM) assay [76,78]. Recently KIN59 was shown to inhibit 
the angiogenic factor fibroblast growth factor-2 (FGF2), suggesting that it might play a role 
in multitargeted antiangiogenic cancer therapy [79]. 
Finally, Metformin which is an anti-diabetic drug recently shown to inhibit cancer cell 
proliferation and growth, was used to treat NSCLC cell lines in an experiment by Ko and 
colleagues [80]. Metformin treatment decreased cellular TP mRNA and protein levels by 
down-regulating phosphorylated MEK1/2-ERK1/2 protein levels in a dose- and time-
dependent manner. Authors proposed that TP downregulation is a mechanism by which 
metformin exerts its cytotoxic effects. 
 
Conclusion 
The complex role of TP in tumour progression and treatment is an example of the complexity 
of cancer biology. In one hand TP enhances metastasis, invasion, angiogenesis and cell death 
evasion. On the other hand, it is crucial for activation of widely use chemotherapy agents like 
capecitabine. Reviewing TP biology is a reminder that malignant cells do not progress in a 
vacuum. The malignant process is a complex one involving non-malignant cells and 
inflammatory factors that are reprogrammed to be in the advantage of cancer cell survival and 
growth [81]. One should not see TP role in cancer in isolation, it has be seen in context of the 
proinflammatory microenvironment of tumour, an environment that indeed promotes 
malignant progression. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
The clinical importance of TP inhibition is yet to be fully defined. TP is widely expressed in 
human cancers and is associated with tumour progression. Research has shown that TP has a 
predictive value particularly in oral flouropyrimidines. However, using TP as a biomarker in 
clinical practise needs standardization of the methods we use to assess its expression and for 
that to be tested in prospective clinical studies. The recently published phase II trial examined 
a combination of TP and TS inhibitors, known as TAS-102. Results of this trial showed that 
TAS-102 is a promising addition to the treatment of colorectal cancer patients refractory to 
standard chemotherapy [70].  Further translational research and clinical prospective trials in 
predictive value and therapeutic targeting of TP are required to expand our knowledge of this 
promising area. 
 
 
 
 
  
Figure 1: Enzymatic reactions catalysed by TP. 
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Figure 2: TP is overexpressed in response to cellular stress conditions like hypoxia, low PH and exposure to 
chemotherapy; TP then exerts its different biological effects.  
TP= Thymidine Phosphorylase. TNFα= Tumor necrosis factor α. HIF2α= Hypoxia inducible factor 2α. 
IFN=Interferon. MMP= Matrix metalloprotease. EC= Endothelial cells. FAK= Focal adhesion kinase. bFGF= b 
fibroblast growth factor. IL= Interleukin. BNIP3= BCL2/adenovirus E1B 19 kDa protein-interacting protein. 
BAX= Bcl-2-associated X protein. 
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